Over
Professor Susana Banerjee is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust, and Professor in Women’s Cancers at The Institute of Cancer Research. She is also the current President of the Royal Society of Medicine Oncology Section. Internationally recognised for her leadership in gynaecological oncology, she specialises in ovarian cancer and the systemic treatment of endometrial and cervical cancers.
Professor Banerjee graduated with First Class Honours in Physiology from St John’s College, University of Cambridge, where she also served as President of the Cambridge Medical Society. She completed her medical degree at The Royal Free and University College London Medical School, finishing as a University of London Gold Medal finalist. She went on to earn a PhD from The Institute of Cancer Research in 2009, receiving the prestigious San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Award for her research. Her achievements have been recognised with multiple awards, including the Association of Cancer Physicians McElwain Prize, the Sir Antony Driver Prize, the Pfizer BOA Young Investigator Award (highly commended), and the Fellow of ESMO (FESMO) Award in 2023.
Throughout her career, Professor Banerjee has played major roles in international oncology leadership. She has served on specialist committees for the European Organization for Research and Treatment of Cancer, the European Society of Gynaecological Oncology, and the International Gynecologic Cancer Society. She was elected to the Executive Board of the European Society for Medical Oncology as Director of Membership from 2020 to 2022, and has held key scientific leadership positions at major global conferences, including ESMO Congress, ESMO Asia, and the ESMO Gynaecological Cancers Congress. She currently co-chairs the GCIG Rare Cancers Committee and serves as Theme Lead for Cancer Treatment Effects at the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research.
A highly respected clinical scientist, Professor Banerjee has authored more than 185 peer-reviewed publications in leading journals such as The New England Journal of Medicine, The Lancet, Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology. Her research focuses on personalised cancer treatment, targeted therapies including PARP inhibitors, and rare gynaecological cancers. She has served as Global or UK Chief Investigator for over 30 national and international clinical trials.
Professor Banerjee graduated with First Class Honours in Physiology from St John’s College, University of Cambridge, where she also served as President of the Cambridge Medical Society. She completed her medical degree at The Royal Free and University College London Medical School, finishing as a University of London Gold Medal finalist. She went on to earn a PhD from The Institute of Cancer Research in 2009, receiving the prestigious San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Award for her research. Her achievements have been recognised with multiple awards, including the Association of Cancer Physicians McElwain Prize, the Sir Antony Driver Prize, the Pfizer BOA Young Investigator Award (highly commended), and the Fellow of ESMO (FESMO) Award in 2023.
Throughout her career, Professor Banerjee has played major roles in international oncology leadership. She has served on specialist committees for the European Organization for Research and Treatment of Cancer, the European Society of Gynaecological Oncology, and the International Gynecologic Cancer Society. She was elected to the Executive Board of the European Society for Medical Oncology as Director of Membership from 2020 to 2022, and has held key scientific leadership positions at major global conferences, including ESMO Congress, ESMO Asia, and the ESMO Gynaecological Cancers Congress. She currently co-chairs the GCIG Rare Cancers Committee and serves as Theme Lead for Cancer Treatment Effects at the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research.
A highly respected clinical scientist, Professor Banerjee has authored more than 185 peer-reviewed publications in leading journals such as The New England Journal of Medicine, The Lancet, Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology. Her research focuses on personalised cancer treatment, targeted therapies including PARP inhibitors, and rare gynaecological cancers. She has served as Global or UK Chief Investigator for over 30 national and international clinical trials.
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Professor Susana Banerjee
Opleiding & training
-
2017–2023 MD · Medicine and Surgery
-
2023–2027 Residency · Oncologie
Carrière & aanstellingen
-
2027-09–2028-08 Junior consultant
Vergunningen & verzekering
Medische licenties
GB — Organización Médica Colegial de España (OMC)
Boardcertificeringen
European Board of Oncologie
Beroepsaansprakelijkheidsverzekering:
AmTrust Europe · 1,000,000 EUR dekking · No claims on file
Uitgevoerde procedures
| Procedure | Code | Levenslang aantal |
|---|---|---|
| GP consultation | 99213 | 731 |
| Annual physical exam | 99395 | 789 |
| Vaccination administration | 90471 | 501 |
| Minor procedure (skin) | 17110 | 1,258 |
Diensten & prijzen
| Dienst | Duur | Modaliteit | Prijs |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 90 min | in_clinic | 720.00 EUR |
| Minor procedure (skin) | 60 min | in_clinic | 630.00 EUR |
Praktijk, team & in praktijk
Video's
Onderzoek & publicaties
h-index: 20 · i10: 5
-
Validation of clinical scoring in Oncologie
DOI: 10.6391/euroclin.2026.0 · PMID: 35588298 · geciteerd door 131
-
Long-term follow-up of Oncologie across GB
DOI: 10.2785/euroclin.2025.1 · PMID: 36302018 · geciteerd door 41
-
Validation of clinical scoring in Oncologie
DOI: 10.6621/euroclin.2024.2 · PMID: 30906490 · geciteerd door 151
-
Long-term follow-up of Oncologie across GB
DOI: 10.3758/euroclin.2023.3 · PMID: 33369808 · geciteerd door 29
Uitgenodigde lezingen
- Practical updates in Oncologie European Annual Congress (Oncologie) · Vienna · 2024 · invited
- Single-centre experience in Oncologie National Society Meeting · London · 2023 · oral abstract
Onderscheidingen & lidmaatschappen
Onderscheidingen
- 🏆 Top-rated Oncologie — London · EuroClinics Patient Choice · 2025 · regional
- 🏆 Excellence in Patient Care · National Society · 2024 · national
- 🏆 Young Investigator Award · European Society · 2023 · international
Lidmaatschappen
- WONCA Europe — Family Doctors — Member · Sinds 2028
- national college of family doctors — Member · Sinds 2028
- European Union of Medical Specialists (UEMS) — Member · Sinds 2028
Artikelen van deze arts
- Patient education Patient guide to Oncologie
- Awareness When should you see a oncologie?
Voor internationale patiënten
- Coördinator
- Patient liaison · dr.susana.banerjee@euroclinics.example
- Geaccepteerde internationale verzekeringen
- Allianz Worldwide · AXA Global · BUPA Global · Cigna Global
Locatie
1 tagPatiëntbeoordelingen
2 geverifieerde recensies5.00
★★★★★
2 recensies
- Bedside Manner
- 5.0
- Knowledge
- 5.0
- Wait Time
- 4.8
- Staff Friendliness
- 5.0
- Ease Of Appointment
- 4.9
- Value For Money
- 4.9
- Would Recommend Pct
- 99.0
Deel uw ervaring — help andere patiënten de juiste arts te vinden. Schrijf een recensie →
Recente recensies
-
★★★★★ ✓ Geverifieerd Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.
-
★★★★★ ✓ Geverifieerd Took time to listen and reviewed all my previous results. I would absolutely recommend.
-
★★★★☆ ✓ Geverifieerd Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.